Additional therapies that have shown efficacy in patients with post-allo-HCT relapse include sorafenib for FLT3+ AML (77, 78), eprenetapopt for TP53-mutated AML (79), and menin inhibitors for NPM1-mutated and MLL-rearranged AML (80, 81). Here, NPM1 is linked to acute myeloid leukemia.